MedTrace Logo

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

NCT04173013 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-09-29

No results posted yet for this study

Summary

An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

Conditions

  • Urinary Tract Infections
  • Chronic Urinary Tract Infection
  • Recurrent Urinary Tract Infection
  • Urinary Tract Infection Bacterial
  • Bladder Infection

Interventions

BIOLOGICAL

Uromune

2 sprays of solution once daily for a total of 3 months.

Sponsors & Collaborators

  • Inmunotek S.L.

    collaborator INDUSTRY

  • Impatients N.V. trading as myTomorrows

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Belgium
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Luxembourg
  • Netherlands
  • Norway
  • Romania
  • Serbia
  • Slovakia
  • Slovenia
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173013 on ClinicalTrials.gov